# Aptensio XR ### (methylphenidate hydrochloride) **[Aptensio XR](https://wiki.joshnp.com/books/drug-library/page/aptensio-xr)** (methylphenidate hydrochloride); CII
[**Full Prescribing Information**](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66&type=display)[**DailyMed Drug Information**](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66)
--- ### **Summary** Aptensio XR is a long-acting methylphenidate CNS stimulant supplied as a multilayer-bead extended-release capsule, approved for ADHD from age 6 with no upper age limit. Each bead carries an immediate-release layer over a controlled-release layer, producing two plasma peaks from one morning dose. The capsule may be opened and sprinkled on applesauce, which is its practical advantage over a swallow-whole osmotic tablet. Schedule II; brand and generic. --- ### **Forms & Strengths** - Extended-release capsules (multilayer beads, may be opened onto applesauce): 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg --- ### **Dosing** - **Age:** >= 6y; no upper limit - **Onset:** ~ 1 hour - **Duration:** up to 12 hours - **Release Profile:** 40% IR / 60% ER via multilayer beads - **Initial Dose:** 10 mg once daily in the morning - **Titration:** 10 mg every 7 days - **Max Dose:** 60 mg/day - **Considerations:** May be swallowed whole or opened onto applesauce, but never divided, so the ladder moves in whole capsules only. --- ### **Pharmacology** - **Mechanism:** Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses - **Delivery / Release:** 40% IR / 60% ER via multilayer beads. Initial peak at about 2 hours, a dip over 4 to 6 hours, then a second peak at about 8 hours. - **Metabolism:** De-esterified to ritalinic acid, inactive. No CYP pathway. Terminal half-life about 5.1 hours; ~90% recovered in urine, so renal impairment has little effect. - **Class Positioning:** Racemic, unlike dexmethylphenidate products. Against [Concerta](https://wiki.joshnp.com/link/11) it trades an ascending profile for two peaks and can be opened; not interchangeable with [Metadate CD](https://wiki.joshnp.com/link/24) or [Ritalin LA](https://wiki.joshnp.com/link/30). - **Alcohol:** at 40% alcohol, 96% of the dose released within two hours in vitro. Dose dumping is a real risk in an adolescent who drinks. --- ### **Indications** - **ADHD** (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients ≥ 6 y/o --- ### **Off-Label Uses** - **Narcolepsy** (ICD-10: G47.411, G47.419): IR methylphenidate carries this indication, Aptensio XR does not. Extrapolates from the moiety, not the product; limited data. - **ADHD in children 4 to under 6 years** (ICD-10: F90.x): **the label records evidence against.** 50% (20 of 39) dropped 10 or more weight percentiles, on exposure 2 to 3 fold higher. Benefits do not outweigh risks. - **Treatment-resistant depression augmentation** (ICD-10: F32.x, F33.x): adult literature only; insufficient in children. - **Cognitive enhancement in youth without ADHD:** not an indication and not supported. --- ### **Contraindications & Warnings** - **Boxed Warning:** Abuse, misuse and addiction, with overdose and death; risk rises with dose and non-oral routes. Assess abuse risk before prescribing and reassess throughout treatment. - **Contraindicated:** - Hypersensitivity to methylphenidate; angioedema and anaphylaxis reported - MAOI use, current or within 14 days: hypertensive crisis - **Use with caution:** - Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid - Pre-existing hypertension: mean rises 2 to 4 mmHg and 3 to 6 bpm, individually larger - Psychotic or bipolar disorder: exacerbation and treatment-emergent mania - Personal or family history of tics or Tourette's syndrome - Significant hyperopia or angle-closure risk: refer to ophthalmology - Substance use disorder in patient or household - **Screen before starting:** - Cardiac history and exam, plus family history of sudden death; mandatory in section 2.1 - Tics or Tourette's, personal and family, with clinical evaluation; also mandatory - Risk factors for a manic episode: depressive symptoms, family history of bipolar disorder or suicide - Abuse and diversion risk in patient and household - Baseline height, weight, blood pressure and heart rate --- ### **Drug Interactions** - **MAOIs** (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days. - **Antihypertensives:** effectiveness reduced. Increase BP monitoring and adjust the antihypertensive. - **Halogenated anesthetics** (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold on the day of surgery. - **Risperidone:** EPS may increase when either dose changes in either direction. Monitor across any titration. - **Serotonergic agents** (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only. Counsel on symptoms rather than avoiding. - **Alcohol:** a formulation interaction, not a pharmacologic one; 96% released within two hours at 40% alcohol. Counsel adolescents explicitly. --- ### **Administration** - Once daily in the morning. The label asks for a consistent routine with meals rather than fed or fasted. - Swallow whole, or sprinkle the entire contents onto applesauce and eat at once without chewing. Never store a sprinkled dose. - Never divide a capsule. Sprinkling is a swallowing accommodation, not a way to split a dose. - A high-fat meal blunts or removes the second peak and raises Cmax ~28%. An erratic breakfast makes the afternoon erratic. - Missed dose: give the next as scheduled. Never double up or give a first dose late in the day. - Store locked; dispose of unused capsules through a take-back program. --- ### **Side Effects** - **Common, pediatric 6 to 17 y** (vs placebo): headache 10.9% vs 8.5%, insomnia 9.8% vs 2.1%, upper abdominal pain 8.2% vs 0%, decreased appetite 4.9% vs 0%, nausea 3.8%, vomiting 3.8%. - **Serious:** - Sudden death with structural cardiac disease: avoid the drug rather than monitor through it - New psychosis or mania, ~0.1% pooled, including with no psychiatric history: consider discontinuing - Priapism, sometimes surgical, typically after a dose increase and also during drug holidays - Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit - Growth suppression: about 2 cm and 2.7 kg less over 3 years - Acute angle closure glaucoma; new or worsening tics and Tourette's: discontinue if appropriate - Hypersensitivity including angioedema and anaphylaxis - Postmarketing: severe hepatic injury, serotonin syndrome, seizures including grand mal, rhabdomyolysis, pancytopenia --- ### **Monitoring & Labs** - **Cardiovascular:** BP and HR at baseline, at each dose change, and every 6 months. - **Growth:** height, weight and BMI at baseline and every 6 months. Crossing two percentile lines is a labeled trigger to interrupt. - **Appetite and sleep:** at every visit; both are dose-timing problems before they are drug problems. - **Psychiatric and tics:** screen for psychosis, mania, aggression and tics at every visit and after each dose increase. - **Digital perfusion:** inspect fingers and toes at each visit for colour change or ulceration. - **Ocular:** no routine schedule; refer before starting in significant hyperopia, and at any new eye pain or halos. - **Abuse and diversion:** at every refill, capsule count, ask about sharing and selling, check the PDMP. A boxed-warning obligation. - **Laboratory:** none required. Check LFTs only for jaundice, dark urine or unexplained fatigue. - **Efficacy stopping rule:** discontinue if no improvement after appropriate dose adjustment over one month. A labeled instruction. --- ### **Discontinuation & Taper** - Can be stopped abruptly at therapeutic doses; the label gives no taper schedule. - Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite. Do not read it as relapse. - Reduce or discontinue for paradoxical worsening or adverse reactions. - Drug holidays are reasonable where growth limits treatment. Priapism has been reported during holidays and on discontinuation. --- ### **Pregnancy & Lactation** - **Pregnancy:** human data are limited and insufficient to inform a drug-associated risk. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%. Weigh against untreated maternal ADHD. - **Lactation:** infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case. Monitor for agitation, poor feeding and reduced weight gain. Not a reason to stop breastfeeding. (LactMed 2025) - **Lactation, milk supply:** prolactin falls; large doses may interfere before supply is established. (LactMed 2025) - **Exposure Registry:** National Pregnancy Registry for Psychostimulants, 1-866-961-2388. --- ### **Counseling Points** - **Counsel the family on:** - The two-peak profile: a mid-morning dip, then coverage to about 12 hours. Unwarned families read the dip as too low a dose. - Sprinkling onto applesauce, eaten straight away without chewing, never saved for later. - Never splitting a capsule; the ladder moves in whole capsules only. - Keeping breakfast consistent; a fatty breakfast on some days and none on others changes the afternoon. - Moving the largest meal to breakfast and the evening, since appetite suppression peaks midday. - Locked storage; sharing or selling a Schedule II medication is a felony. - For adolescents, that alcohol can release almost the whole capsule at once. Specific to this formulation. - **Advise them to call for:** - Chest pain, fainting, or a racing heart that does not settle. - New hallucinations, or new suspicious or fearful thinking. - Numbness, coldness, or colour change in the fingers or toes. - A new or markedly worse tic, or a new vocal tic. - Weight loss, or clothes fitting more loosely over a few weeks. - A painful erection lasting more than a few hours, which is a surgical emergency. - Yellowing of the eyes or skin, dark urine, or new eye pain with halos around lights. --- ### **References** 1. DailyMed. Aptensio XR (methylphenidate hydrochloride) extended-release capsules prescribing information. Rhodes Pharmaceuticals LLC. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66 2. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/ 3. FDA. openFDA National Drug Code Directory, methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic\_name:%22methylphenidate%22 4. AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/ 5. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/ 6. DEA. Drug scheduling. Methylphenidate is a Schedule II controlled substance. https://www.dea.gov/drug-information/drug-scheduling